Results 121 to 130 of about 34,080 (270)
g-Nomic: a new pharmacogenetics interpretation software
, 2019 Ana Sabater,1 Carlos J Ciudad,2 Marc Cendros,1 Denis Dobrokhotov,1 Juan Sabater-Tobella11Department of Information Technology, EUGENOMIC, Barcelona 08012, Spain; 2Department of Biochemistry and Physiology, University of Barcelona, Barcelona 08028 ...
Dobrokhotov D +4 more
core
ABCB1 Frameshift Deletion in Skye Terriers With Potential Pharmacogenetic Relevance
Animal Genetics, Volume 57, Issue 5, October 2026.ABSTRACT Ivermectin‐associated neurotoxicity is a potentially life‐threatening condition caused by disruption of the ABCB1 encoded P‐glycoprotein drug transporter in certain dog breeds. Skye terriers are considered at increased risk of ivermectin toxicity despite the absence of an identified molecular cause.
Monica Nielsen +4 more
wiley +1 more source
Association of TNF and TLR2 genes with blood parameter levels in Mexican patients with schizophrenia
BMC PsychiatryBackground Clinical and genetic studies have suggested that immune dysregulation and neuroinflammation are involved in the pathogenesis of schizophrenia.
Héctor Cabello-Rangel +5 more
doaj +1 more source
Pharmacogenetics and the Blood–Brain Barrier: A Whirlwind Tour of Potential Clinical Utility
Future PharmacologyGenetic factors influence medication response (pharmacogenetics), affecting the pharmacodynamics and pharmacokinetics of many medicaments used in clinical care.
David R. Skvarc +5 more
doaj +1 more source
Clinical Pharmacology &Therapeutics, Volume 120, Issue 4, Page 966-978, October 2026.This study investigated genetic determinants of the pharmacokinetics of the CYP2C8 index drugs repaglinide and gemfibrozil, and their interaction in healthy participants. Sequencing data from a study with montelukast revealed a novel functional CYP2C8 allele (rs2071426, CYP2C8*19), predicted to create an intronic splice donor site.
Anssi J. H. Mykkänen +14 more
wiley +1 more source
Inhibition of iRhom1 by CD44-targeting nanocarrier for improved cancer immunochemotherapy
Nature CommunicationsThe multifaceted chemo-immune resistance is the principal barrier to achieving cure in cancer patients. Identifying a target that is critically involved in chemo-immune-resistance represents an attractive strategy to improve cancer treatment.
Zhangyi Luo +17 more
doaj +1 more source
Induction of Cyp2e1 contributes to asparaginase-induced hepatocyte sensitization to lipotoxicity
Acta Pharmaceutica Sinica BOne of the leading therapies for acute lymphoblastic leukemia (ALL) is the chemotherapeutic agent PEGylated E. coli-derived-l-asparaginase (PEG-ASNase).
Yin Zhu +7 more
doaj +1 more source
Clinical Pharmacology &Therapeutics, Volume 120, Issue 4, Page 937-942, October 2026.Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel is commonly used for secondary prevention following acute ischemic stroke (AIS) and neurointerventional procedures. However, the efficacy of clopidogrel is reduced in carriers of CYP2C19 no‐function alleles.
Rachael M. Stone +11 more
wiley +1 more source
Clinical Pharmacology &Therapeutics, Volume 120, Issue 4, Page 1101-1110, October 2026.NAT2 encodes arylamine N‐acetyltransferase 2, a key enzyme in the phase II metabolism of arylamines and arylhydrazines. NAT2 is highly polymorphic, resulting in variable distributions of rapid and poor metabolizers across global populations. Here, we detail the process undertaken by the Clinical Pharmacogenetics Implementation Consortium (CPIC) NAT2 ...
Bailey M. Tibben +10 more
wiley +1 more source